Virtu Financial’s Solid Biosciences SLDB Stock Holding History

Virtu Financial’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-59,739	Closed	-$430K	–	2188
2026 Q1	$430K	Buy	+59,739	New	+$384K	0.02%	632
2025 Q2	–	Sell	-25,742	Closed	-$95K	–	1995
2025 Q1	$95K	Buy	+25,742	New	+$110K	0.01%	929
2022 Q4	–	Sell	-945	Closed	-$7K	–	2086
2022 Q3	$7K	Buy	+945	New	+$9.53K	﹤0.01%	1556
2019 Q2	–	Sell	-1,349	Closed	-$186K	–	1818
2019 Q1	$186K	Buy	+1,349	New	+$338K	0.01%	1025

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Virtu Financial's SLDB Position: Q2 2026 in Review

Virtu Financial sold out of Solid Biosciences (SLDB) in Q2 2026, closing a stake of 59,739 shares — an estimated $430K sold.

Virtu Financial first reported a position in SLDB in Q1 2019 and held it in 4 quarters. The position peaked at $430K in Q1 2026. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

Virtu Financial reported no remaining Solid Biosciences position as of Q2 2026 after selling out during the quarter.
Virtu Financial sold 59,739 Solid Biosciences shares in Q2 2026, an estimated $430K.
Virtu Financial first reported a position in Solid Biosciences in Q1 2019 and held it in 4 quarters.
Virtu Financial's Solid Biosciences position peaked at $430K in Q1 2026.
157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.